197 institutions hold shares in Amneal Pharmaceuticals Inc. (AMRX), with 15.21M shares held by insiders accounting for 10.29% while institutional investors hold 66.03% of the company’s shares. The shares outstanding are 147.64M, and float is at 116.74M with Short Float at 3.50%. Institutions hold 59.23% of the Float.
The top institutional shareholder in the company is Fosun International Ltd with over 21.52 million shares valued at $98.35 million. The investor’s holdings represent 14.50% of the AMRX Shares outstanding. As of Dec 30, 2020, the second largest holder is Tpg Group Holdings (sbs) Advisors, Inc. with 16.21 million shares valued at $74.1 million to account for 10.92% of the shares outstanding. The other top investors are Wellington Management Group, LLP which holds 13.91 million shares representing 9.37% and valued at over $63.55 million, while Vanguard Group, Inc. (The) holds 7.40% of the shares totaling 10.98 million with a market value of $50.19 million.
Amneal Pharmaceuticals Inc. (NYSE: AMRX) is 23.19% higher on its value in year-to-date trading and has touched a low of $3.24 and a high of $7.45 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AMRX stock was last observed hovering at around $5.71 in the last trading session, with the day’s loss setting it -0.08% off its average median price target of $6.50 for the next 12 months. It is also 37.44% off the consensus price target high of $9.00 offered by 11 analysts, but current levels are -87.67% lower than the price target low of $3.00 for the same period.
Currently trading at $5.63, the stock is -6.85% and -5.88% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.76 million and changing -1.40% at the moment leaves the stock 15.96% off its SMA200. AMRX registered 55.10% gain for a year compared to 6-month gain of 16.32%. The firm has a 50-day simple moving average (SMA 50) of $6.31 and a 200-day simple moving average (SMA200) of $5.14.
The stock witnessed a -16.96% loss in the last 1 month and extending the period to 3 months gives it a 16.56%, and is -3.10% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.70% over the week and 4.20% over the month.
Amneal Pharmaceuticals Inc. (AMRX) has around 5500 employees, a market worth around $1.70B and $1.99B in sales. Fwd P/E is 6.41. Profit margin for the company is 4.60%. Distance from 52-week low is 73.77% and -24.38% from its 52-week high. The company has generated returns on investments over the last 12 months (2.70%).
Amneal Pharmaceuticals Inc. (AMRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Amneal Pharmaceuticals Inc. (AMRX) is a “Overweight”. 11 analysts offering their recommendations for the stock have an average rating of 2.40, where 5 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Amneal Pharmaceuticals Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at $0.18 with sales reaching $515.34M over the same period.The EPS is expected to grow by 95.40% this year, but quarterly earnings will post 7.40% year-over-year. Quarterly sales are estimated to grow 3.40% in year-over-year returns.
Amneal Pharmaceuticals Inc. (AMRX) Insider Activity
A total of 21 insider transactions have happened at Amneal Pharmaceuticals Inc. (AMRX) in the last six months, with sales accounting for 9 and purchases happening 12 times. The most recent transaction is an insider sale by Shah Nikita, the company’s Executive Vice President. SEC filings show that Shah Nikita sold 36,330 shares of the company’s common stock on Mar 15 at a price of $6.87 per share for a total of $0.25 million. Following the sale, the insider now owns 0.21 million shares.
Amneal Pharmaceuticals Inc. disclosed in a document filed with the SEC on Mar 15 that Todisco Joseph (Executive Vice President) sold a total of 36,330 shares of the company’s common stock. The trade occurred on Mar 15 and was made at $6.82 per share for $0.25 million. Following the transaction, the insider now directly holds 0.28 million shares of the AMRX stock.
Still, SEC filings show that on May 19, Kiely John (Director) acquired 10,000 shares at an average price of $4.40 for $44000.0. The insider now directly holds 10,000 shares of Amneal Pharmaceuticals Inc. (AMRX).